Monteklust all pharmacological information
Reading File
Finding Sources
Finding Sources
Searching the Web
montelukast pharmacology mechanism dose side effects 2025
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the full pharmacological profile of Montelukast:
Montelukast (Singulair) - Complete Pharmacological Profile
1. Drug Classification
| Property | Detail |
|---|---|
| Class | Leukotriene receptor antagonist (LTRA) |
| Subclass | Selective cysteinyl leukotriene-1 (CysLT1) receptor antagonist |
| Brand name | Singulair |
| Route | Oral (tablet, chewable tablet, granules) |
2. Mechanism of Action
Leukotrienes (LTC4, LTD4, LTE4) are cysteinyl leukotrienes synthesized via the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism. They are produced by mast cells, basophils, eosinophils, and neutrophils in response to allergen or IgE receptor activation.
Cysteinyl leukotrienes exert three key pathological effects:
- Bronchoconstriction (smooth muscle contraction)
- Increased vascular permeability (mucosal edema)
- Enhanced mucus secretion and bronchial hyperresponsiveness
Montelukast selectively and competitively blocks the CysLT1 receptor on airway smooth muscle and nasal tissues, preventing LTD4 (the most potent bronchoconstrictor among leukotrienes) and its related cysteinyl leukotrienes from binding. This interrupts the downstream inflammatory cascade. It does not inhibit leukotriene synthesis (unlike zileuton, which blocks 5-lipoxygenase).
- Lippincott Illustrated Reviews: Pharmacology, p. 1396
- Katzung's Basic and Clinical Pharmacology, 16th Edition, p. 565
3. Pharmacokinetics
| Parameter | Detail |
|---|---|
| Absorption | Rapidly absorbed orally; bioavailability 63-73%; food does NOT impair absorption (unlike zafirlukast) |
| Protein binding | ~99% bound to plasma proteins |
| Metabolism | Extensive hepatic metabolism via CYP3A4, CYP2C8, CYP2C9 |
| Half-life | 2.7 - 5.5 hours |
| Excretion | Primarily biliary/fecal (montelukast and metabolites undergo biliary excretion); minimal renal excretion |
| Administration timing | Taken once daily in the evening (for asthma); can be taken without regard to meals |
- Lippincott Illustrated Reviews: Pharmacology, p. 1396
- Fishman's Pulmonary Diseases and Disorders
4. Indications (Approved Uses)
| Indication | Age | Notes |
|---|---|---|
| Chronic persistent asthma (prophylaxis/maintenance) | ≥2 years | Not for acute attacks |
| Allergic rhinitis - seasonal | Adults & children | Equal efficacy to antihistamines; inferior to intranasal corticosteroids |
| Allergic rhinitis - perennial | Adults & children | Approved |
| Exercise-induced bronchoconstriction (EIB) prevention | ≥6 years | Used as pre-exercise prophylaxis |
| Aspirin-exacerbated respiratory disease (AERD) | Adults | Leukotrienes are central mediators |
| Asthma with concurrent allergic rhinitis | All ages | Dual benefit; widely used in children |
Important: Montelukast is a prophylactic/controller drug. It has no role in managing acute asthma exacerbations and should not be used for quick relief of bronchospasm.
- Katzung's Basic and Clinical Pharmacology, p. 565
- Cummings Otolaryngology Head and Neck Surgery
- Fishman's Pulmonary Diseases and Disorders
5. Dosing
| Age Group | Dose | Formulation |
|---|---|---|
| Adults & adolescents ≥15 years | 10 mg once daily (evening) | Film-coated tablet |
| Children 6-14 years | 5 mg once daily (evening) | Chewable tablet |
| Children 2-5 years | 4 mg once daily | Chewable tablet or granules |
| EIB prevention (adults) | 10 mg at least 2 hours before exercise | Single dose; no additional dose same day |
- StatPearls / NIH and drugs.com, updated September 2025
6. Adverse Effects
Common (mild)
- Headache
- Abdominal pain, diarrhea, dyspepsia
- Cough, upper respiratory infection symptoms
- Ear pain/fullness
- Fever, flu-like symptoms
Serious - BLACK BOX WARNING (FDA)
Neuropsychiatric events - reported across all age groups (adults, adolescents, children):
- Anxiety, depression, agitation, aggression, irritability
- Confusion, memory and attention impairment
- Sleep disturbances: insomnia, somnambulism (sleepwalking), vivid dreams
- Tremors, stuttering, uncontrolled muscle movements
- Hallucinations
- Suicidal thoughts and behavior
Patients should be monitored regularly for mood or behavior changes. If neuropsychiatric signs develop, discontinue montelukast and contact a physician immediately.
Rare but serious
- Eosinophilic Granulomatosis with Polyangiitis (EGPA) - formerly Churg-Strauss syndrome: presents with eosinophilia, vasculitis, rash, neuropathy, worsening respiratory symptoms. Often temporally related to introduction of montelukast, particularly during corticosteroid tapering. Onset typically 6-18 months after initiation. Remission observed upon drug discontinuation ± corticosteroid reinstitution.
- Allergic reactions: anaphylaxis, angioedema, urticaria
Hepatotoxicity
-
Hepatic enzyme elevations are more characteristic of zileuton and zafirlukast; montelukast has a comparatively safer hepatic profile, but liver function should still be considered in context.
-
Lippincott Illustrated Reviews: Pharmacology, p. 1396
-
Murray & Nadel's Textbook of Respiratory Medicine
-
Fishman's Pulmonary Diseases and Disorders
7. Contraindications
| Contraindication | Reason |
|---|---|
| Phenylketonuria (PKU) | Chewable tablets contain phenylalanine |
| Hypersensitivity to montelukast | Anaphylaxis risk |
8. Drug Interactions
Montelukast is a substrate of CYP3A4, CYP2C8, and CYP2C9. Key interactions:
| Interacting Drug/Class | Mechanism | Effect |
|---|---|---|
| CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort) | Increased montelukast metabolism | Reduced plasma levels; possible loss of efficacy |
| CYP2C8 inhibitors (gemfibrozil) | Decreased montelukast metabolism | Increased montelukast exposure |
| Phenobarbital | CYP inducer | Decreased montelukast AUC by ~40% |
Note: Zafirlukast (a related LTRA) is a CYP inhibitor (2C8, 2C9, 3A4) and has more pronounced interaction potential than montelukast.
9. Special Populations
| Population | Consideration |
|---|---|
| Pregnancy | Use with caution; limited data; generally considered relatively safe when benefit outweighs risk |
| Pediatrics (<2 years) | Not approved |
| Phenylketonuria | Avoid chewable tablets (contain phenylalanine); use granules or regular tablets |
| Hepatic impairment | Use with caution; dosing adjustment generally not required for mild-moderate impairment |
| Renal impairment | No dose adjustment required (predominantly biliary excretion) |
10. Comparative Position Among Antileukotriene Agents
| Agent | Mechanism | Key Difference vs. Montelukast |
|---|---|---|
| Montelukast | CysLT1 receptor blocker | Most widely used; once daily; approved from age 2 |
| Zafirlukast | CysLT1 receptor blocker | Food impairs absorption; approved from age 6; inhibits CYP (more drug interactions) |
| Pranlukast | CysLT1 receptor blocker | Available only in Japan |
| Zileuton | 5-Lipoxygenase inhibitor | Blocks all leukotriene synthesis; slightly more effective; requires LFT monitoring; approved from age 12 |
- Katzung's Basic and Clinical Pharmacology, p. 565
- Lippincott Illustrated Reviews: Pharmacology, p. 1396
11. Place in Therapy
-
Considered an alternative (not first-line) controller for mild-to-moderate asthma when inhaled corticosteroids (ICS) cannot be used or tolerated
-
Less effective than ICS for asthma control; less effective than intranasal corticosteroids for allergic rhinitis
-
Equal efficacy to antihistamines for AR symptoms but not recommended as routine monotherapy for AR due to inferior efficacy and higher cost compared to other first-line agents (AAO-HNS guideline, ICAR-AR 2018 consensus)
-
Particularly useful when a patient has both asthma AND allergic rhinitis (one oral tablet treats both)
-
Preferred in children with exercise-induced or aspirin-exacerbated asthma
-
Cannot replace SABA for acute bronchospasm
-
Cummings Otolaryngology, p. 3129
-
Katzung's Basic and Clinical Pharmacology, p. 565
-
Fishman's Pulmonary Diseases and Disorders
12. Overdose / Toxicity
Clinical studies used doses up to 200 mg/day for 22 weeks and 900 mg/day for ~1 week without significant adverse effects. Reported overdose cases (up to 1000 mg) showed relatively benign signs: headache, thirst, somnolence, hyperactivity, vomiting, abdominal pain. No specific antidote exists; management is supportive.
- StatPearls (NIH)
Key takeaway: Montelukast is a selective, once-daily oral CysLT1 receptor antagonist that reduces leukotriene-mediated bronchoconstriction and inflammation. Its main strengths are convenient oral dosing, pediatric approval from age 2, and dual coverage for asthma plus allergic rhinitis. Its most important safety concern is the FDA black box warning for neuropsychiatric adverse events, including suicidal ideation, which requires ongoing monitoring in all patient populations.
Rifampicin
Reading File
Finding Sources
Finding Sources
Searching the Web
rifampicin rifampin complete pharmacology mechanism dose side effects drug interactions 2025
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive data from multiple authoritative textbooks. Here is the complete pharmacological profile:
Rifampicin (Rifampin) - Complete Pharmacological Profile
1. Drug Classification
| Property | Detail |
|---|---|
| Class | Rifamycin antibiotic |
| Type | Semisynthetic derivative of rifamycin B (produced by Streptomyces mediterranei) |
| Brand names | Rifadin, Rimactane |
| Related drugs | Rifabutin, rifapentine (same class, different spectrum/interactions) |
2. Mechanism of Action
Rifampicin binds selectively and specifically to the beta (β) subunit of bacterial DNA-dependent RNA polymerase, thereby:
- Inhibiting initiation of RNA chain formation - it blocks the enzyme from transcribing DNA into mRNA
- Suppressing early elongation of the nucleotide chain in RNA synthesis
- Resulting in rapid bactericidal killing (concentration-dependent activity)
It does not bind mammalian RNA polymerase at therapeutic concentrations, which explains its selective toxicity.
Resistance mechanism: Mutation in the chromosomal gene encoding the β subunit of RNA polymerase (rpoB gene) - the altered subunit can no longer bind rifampicin. This is why resistance develops rapidly if the drug is used as monotherapy, mandating combination use.
- Medical Microbiology 9e
- Murray & Nadel's Textbook of Respiratory Medicine
3. Antibacterial Spectrum
| Organism Category | Activity |
|---|---|
| Mycobacterium tuberculosis | Highly bactericidal; best sterilizing agent against slow/dormant "persisters" in caseous lesions |
| Mycobacterium leprae | Highly bactericidal; single dose 1500 mg kills ~99% of viable organisms |
| Mycobacterium avium (rifabutin preferred) | Active but rifabutin superior |
| Gram-positive cocci | Very active - staphylococci (including MRSA), streptococci |
| Neisseria meningitidis | Active - used for meningococcal prophylaxis |
| Haemophilus influenzae | Active - used for Hib prophylaxis |
| Gram-negative bacilli (most) | Intrinsically resistant - due to decreased uptake of the hydrophobic drug |
| Intracellular organisms | Excellent penetration - kills both intracellular and extracellular bacilli |
A key pharmacological distinction: rifampicin is the only first-line TB drug with bactericidal activity against "persisters" - dormant bacilli in solid caseous lesions. All other drugs are inactive against these populations. This is why rifampicin is critical for shortening TB treatment duration.
- Park's Textbook of Preventive and Social Medicine
- Medical Microbiology 9e
4. Pharmacokinetics
| Parameter | Detail |
|---|---|
| Absorption | Well absorbed orally; food delays and reduces peak concentration - should be taken 1 hour before or 2 hours after food; bioavailability ~90-95% when fasting |
| Distribution | Highly lipophilic; distributes widely into all tissues; crosses blood-brain barrier (adequate CSF penetration with or without inflammation, exceeds usual MICs); crosses placental barrier |
| Protein binding | ~80% bound to plasma proteins |
| Metabolism | Hepatic - undergoes enterohepatic recirculation; auto-induction of its own metabolism (accelerated clearance with repeat dosing over first 2 weeks) |
| Half-life | 3-4 hours (prolonged in hepatic impairment); in end-stage renal disease: 1.8-11 hours |
| Excretion | Primarily fecal/biliary (60-65%); urine (~30%) as unchanged drug; NOT significantly removed by hemodialysis or peritoneal dialysis |
| IV availability | Available; but oral absorption is so complete that parenteral use is rarely needed |
| Bactericidal kinetics | Concentration-dependent killing |
Special note on auto-induction: Rifampicin induces its own CYP metabolism. Plasma levels fall progressively over the first 2 weeks of therapy as hepatic enzymes are upregulated - clinically important when interpreting early therapeutic drug monitoring.
- Medscape Drug Reference, Park's Textbook
5. Indications
Primary (Anti-tuberculous)
- Active pulmonary TB (drug-susceptible): cornerstone of the standard 6-month regimen (HRZE intensive phase + HR continuation phase)
- Extrapulmonary TB: meningitis, skeletal, renal, pericardial, peritoneal
- Latent TB infection (LTBI): 4-month rifampicin (4R) regimen - now preferred over 6-month INH for LTBI in many guidelines
Other Indications
- Leprosy: multidrug therapy (MDT) for paucibacillary and multibacillary leprosy
- Meningococcal prophylaxis (chemoprophylaxis for contacts of N. meningitidis)
- Hib prophylaxis (contacts of H. influenzae type b disease)
- Staphylococcal infections (biofilm-associated, e.g., prosthetic joint infections, endocarditis) - always in combination to prevent resistance
- Brucellosis (combination regimen)
- Legionella pneumonia (severe cases, in combination)
6. Dosing
TB Treatment (Adults - Drug-Susceptible)
| Phase | Regimen | Dose | Duration |
|---|---|---|---|
| Intensive phase | HRZE (INH + RIF + PZA + EMB) | 10 mg/kg/day (typically 600 mg) | 8 weeks (5-7 days/week) |
| Continuation phase | HR (INH + RIF) | 10 mg/kg/day (typically 600 mg) | 18 weeks (5-7 days/week) |
| Thrice-weekly DOT | HR | 10 mg/kg (typically 600 mg) | As per regimen |
Maximum adult dose: 600 mg/day
Pediatric (TB)
- 10-20 mg/kg/day (max 600 mg/day)
Meningococcal Prophylaxis (Adults)
- 600 mg twice daily for 2 days
Leprosy (Multibacillary)
- 600 mg monthly (supervised) as part of WHO MDT
The ATS/CDC/IDSA guideline (2016) is the source for the TB regimen table above. - Goldman-Cecil Medicine
7. Adverse Effects
Common
- GI: Nausea, vomiting, abdominal pain, anorexia, diarrhea (common at initiation, usually transient)
- Red-orange discoloration of urine, tears, saliva, sweat, sputum, and semen - harmless but important to warn patients (useful as a compliance marker; can permanently stain soft contact lenses)
Hepatotoxicity (Most Clinically Important)
- Transient asymptomatic rise in liver transaminases (common)
- Clinical hepatitis - more common when combined with isoniazid
- Risk factors: pre-existing liver disease, alcohol use, old age, malnutrition
- Monitoring: baseline and periodic LFTs required
Immunological / Hypersensitivity (Especially with Intermittent Dosing)
- Flu-like (influenza-like) syndrome - fever, chills, myalgia, headache - associated with high-dose intermittent (twice-weekly) therapy
- Thrombocytopenia - can be severe; immune-mediated; more with intermittent therapy
- Purpura
- Hemolytic anemia
- Acute renal failure (rare; tubular necrosis; associated with intermittent high-dose regimens)
- Shock and collapse - rare but can occur after re-introduction following a gap; patient should be observed for 1 hour after dosing if restarting
Other
- Nephrotoxicity (rare)
- Interstitial nephritis
- Headache, drowsiness, ataxia, confusion (CNS effects, rare)
- Skin rash, pruritus
Important warning: If rifampicin is stopped for any reason, it should NOT be restarted within 3 weeks to avoid a severe hypersensitivity reaction.
- Park's Textbook, Murray & Nadel's
8. Drug Interactions (Major Clinical Concern)
Rifampicin is one of the most potent enzyme inducers in clinical pharmacology. It activates multiple metabolic pathways, dramatically reducing plasma levels of co-administered drugs.
Enzymes and Transporters Induced
| System Induced | Effect |
|---|---|
| CYP3A4 (major) | Most extensive interaction; affects majority of commonly prescribed drugs |
| CYP1A2 | Reduced levels of drugs metabolized by this enzyme |
| CYP2B6 | Relevant for methadone, bupropion |
| CYP2C8 | Relevant for repaglinide, paclitaxel |
| CYP2C9 | Relevant for warfarin, sulfonylureas |
| CYP2C19 | Relevant for PPIs, voriconazole |
| UDP-glucuronosyltransferases (UGT) | Additional glucuronidation induction |
| P-glycoprotein (P-gp) | Increases efflux transport; reduces bioavailability of P-gp substrates |
| MRP2 (multidrug resistance protein 2) | Additional transporter induction |
Critical Drug Interactions by Category
| Drug/Class | Interaction | Clinical Management |
|---|---|---|
| Warfarin | CYP2C9 induction → markedly decreased anticoagulant effect; INR may drop precipitously | Monitor INR closely; increase warfarin dose; reduce again after rifampicin stops |
| Oral contraceptives | CYP3A4 induction → reduced estrogen/progesterone levels → contraceptive failure | Use additional/alternative contraception |
| HIV Protease Inhibitors (atazanavir, darunavir) | Massive reduction in PI levels (~75-90%) | Contraindicated - use rifabutin instead |
| NNRTIs | Efavirenz 600 mg: compatible (can be used together); doravirine, rilpivirine, etravirine: contraindicated | Switch to efavirenz-based ART |
| Corticosteroids | Accelerated steroid metabolism; may precipitate adrenal crisis or loss of effect | Double the steroid dose during rifampicin therapy |
| Azole antifungals (voriconazole, itraconazole) | Dramatically reduced azole levels; voriconazole becomes essentially ineffective | Avoid combination - voriconazole/rifampicin is contraindicated |
| Methadone | CYP2B6/3A4 induction → opiate withdrawal | Increase methadone dose significantly |
| Sulfonylureas (glyburide, glipizide) | CYP2C9 induction → reduced hypoglycemic effect (glyburide AUC reduced 39-63%) | Monitor blood glucose; adjust dose |
| Cyclosporine / tacrolimus | CYP3A4/P-gp induction → subtherapeutic immunosuppression → organ rejection | Dramatically increase calcineurin inhibitor doses (2-5x); monitor levels |
| Raltegravir | UGT1A1 induction → reduced levels | Use with dose adjustment |
| Rifampicin + PAS (para-aminosalicylic acid) | PAS delays rifampicin absorption | Avoid concurrent administration |
| Montelukast | CYP3A4 induction → reduced montelukast levels | Monitor clinical response |
Note: Drug interactions persist for 1-2 weeks after rifampicin discontinuation while enzyme levels normalize. Dose adjustments made during therapy must be reversed after stopping to prevent toxicity.
9. Contraindications
| Contraindication | Reason |
|---|---|
| Hypersensitivity to rifamycins | Anaphylaxis / severe reaction |
| Severe hepatic impairment / active liver disease | Worsened hepatotoxicity risk |
| Coadministration with HIV protease inhibitors | Subtherapeutic PI levels → treatment failure |
| Coadministration with voriconazole | Drug rendered ineffective |
| Restarting within 3 weeks of stopping | Severe hypersensitivity reaction risk |
10. Special Populations
| Population | Consideration |
|---|---|
| Pregnancy | Crosses placenta; Category C - generally used for TB in pregnancy (benefit outweighs risk); associated with postnatal hemorrhage - give vitamin K to neonate and mother at term |
| Neonates/infants | Can be used at adjusted doses |
| Renal impairment | No dose adjustment typically required (predominantly biliary excretion; not removed by dialysis) |
| Hepatic impairment | Use with caution; dose reduction or avoidance in severe disease; half-life prolonged |
| HIV co-infection | Complex interactions with ART - rifampicin is compatible with efavirenz-based regimens; substitute rifabutin for PI-based ART |
| Elderly | Greater hepatotoxicity risk; monitor LFTs |
11. Resistance
- Develops rapidly with monotherapy - always use in combination
- Mechanism: point mutations in rpoB gene (β subunit of RNA polymerase) - detected by GeneXpert MTB/RIF assay
- Rifampicin resistance is used as a surrogate marker for MDR-TB (multidrug-resistant tuberculosis) because rpoB mutations are usually accompanied by or predict INH resistance
- Gram-negative bacteria are intrinsically resistant due to poor drug uptake
12. Monitoring Parameters
| Parameter | Frequency |
|---|---|
| Liver function tests (AST, ALT, bilirubin) | Baseline, then monthly or if symptoms develop |
| Complete blood count | Baseline; if symptoms of thrombocytopenia (bruising, purpura) |
| Renal function | Baseline; especially with intermittent dosing |
| Drug levels of interacting medications (warfarin INR, cyclosporine, ART levels) | Regular monitoring throughout therapy and after discontinuation |
| Clinical compliance check | Red-orange urine serves as practical compliance marker |
13. Comparison with Other Rifamycins
| Drug | Key Differences vs. Rifampicin |
|---|---|
| Rifabutin | Weaker CYP inducer (preferred with HIV PIs); more active against M. avium; causes uveitis, neutropenia |
| Rifapentine | Very long half-life (13-19 hrs); used once weekly with INH for LTBI (3HP regimen); also a potent inducer |
| Rifaximin | Minimally absorbed oral rifamycin; used for traveler's diarrhea, hepatic encephalopathy; no significant systemic induction |
Summary: Rifampicin is a bactericidal rifamycin antibiotic that blocks bacterial RNA synthesis by binding the β subunit of DNA-dependent RNA polymerase. Its defining clinical features are: (1) irreplaceable role in TB treatment as the best sterilizing agent; (2) the ability to kill dormant "persisters"; (3) potent induction of CYP3A4 and other drug-metabolizing enzymes making it a major source of clinically significant drug interactions; (4) characteristic red-orange body fluid discoloration; and (5) necessity for combination use at all times to prevent rapid resistance emergence.
- Murray & Nadel's Textbook of Respiratory Medicine
- Medical Microbiology 9e
- Goldman-Cecil Medicine
- Park's Textbook of Preventive and Social Medicine
- Katzung's Basic and Clinical Pharmacology, 16th Edition
This is a shared conversation. Sign in to Orris to start your own chat.